New drug combo aims to keep viral pneumonia patients out of hospital
Disease control
Terminated
This study tested whether adding the drug silmitasertib to standard care helps adults with viral pneumonia (from COVID-19 or flu) avoid hospitalization or death. About 45 outpatients with mild-to-moderate pneumonia took part. The trial was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: Senhwa Biosciences, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC